Longevity market seen reaching $66.4 billion by 2035

Market Research Future projects the global longevity market will nearly double to $66.40 billion by 2035 from $34.57 billion in 2026, driven by aging populations, senolytic pipeline growth and AI-enabled drug discovery. The forecast points to rising demand across therapeutics, diagnostics and digital health as health systems shift toward extending healthspan rather than just lifespan.

Why it matters: - The longevity market is moving from niche research into a larger commercial category tied to aging populations, chronic disease and healthspan-focused care. - Market Research Future projects the sector will grow from $34.57 billion in 2026 to $66.40 billion by 2035, a 7.52% compound annual growth rate. - The shift matters because it pulls spending toward interventions that delay disease and disability, not just treatments that extend life.

What happened: - Market Research Future published a forecast on July 16, 2026, estimating the global longevity market at $32.15 billion in 2025 before growth accelerates through 2035. - The forecast identifies aging demographics, senolytic and senomorphic pipeline maturation, and AI-driven drug discovery as the main growth drivers. - The report also points to expanding demand for epigenetic clocks, digital biomarkers and mechanism-targeted therapies. - A free sample is available here.

The details: - The United Nations projects the global population aged 65 and older will rise to more than 1.6 billion by 2050 from 761 million in 2021. - Japan already directs more than 34% of its social-security budget to geriatric care. - Germany's statutory health-insurance spending on age-related chronic conditions rose 11% year over year in 2024. - The U.S. National Institute on Aging allocated more than $4.1 billion to aging-related research in fiscal 2024. - China and India are emerging as demand centers as elderly populations and age-related chronic disease burdens rise. - Senolytic small molecules remain the largest therapy segment, with roughly 39.0% revenue share in 2025. - Gene therapy is the fastest-growing therapy category, with a projected 10.65% CAGR from 2026 to 2035. - In-vivo therapeutics held about 66.8% of delivery-platform revenue in 2025. - Digital longevity interventions are the fastest-growing platform, projected at 13.80% CAGR through 2035. - Oncology was the largest application segment in 2025, with about 25.2% revenue share. - Neurodegenerative disorders are the fastest-growing application, projected at 11.36% CAGR. - Pharmaceutical and biotechnology companies were the largest end users in 2025, with about 58.7% revenue share. - Wellness clinics and longevity spas are the fastest-growing end-user segment, projected at 12.12% CAGR. - North America held about 38.0% of the market in 2025, while Europe was the second-largest region at about 28.0%. - Asia-Pacific is the fastest-growing region, projected at 9.52% CAGR from 2026 to 2035. - The Middle East and Africa are projected to grow at 8.45% CAGR, while South America reached $2.09 billion in 2025. - The market remains fragmented, with an estimated Herfindahl-Hirschman Index below 500 and the top five players holding roughly 22% to 28% of global revenue.

Between the lines: - The report shows a market moving from broad longevity branding toward specific clinical and diagnostic use cases that can be measured, priced and reimbursed. - The strongest near-term opportunities appear to sit in oral senolytics, AI-assisted discovery and consumer-facing biological-age testing, because those segments have clearer commercialization paths. - Regulatory signals also matter. The FDA's 2024 draft guidance on surrogate endpoints for age-modifying therapies appears to lower one of the biggest risks for developers. - Competition is still early-stage and fluid, which means clinical readouts can quickly reshape leaderboards. - Named companies with recent milestones include Altos Labs, Calico, Unity Biotechnology, Insilico Medicine and BioAge Labs.

What's next: - By 2030, the report expects AI-driven target discovery and biological-age prediction to become central tools in longevity drug development. - It also expects around 70% of preclinical longevity programs to use generative-AI compound screening. - The report sees theragnostic models, combining diagnostics and therapeutics, becoming more common in the early 2030s. - As costs fall, longevity products are likely to move beyond specialty clinics into primary care, employer wellness programs and direct-to-consumer channels. - Investors and developers will likely watch clinical data, regulatory guidance and regional reimbursement decisions as the main near-term catalysts.

The bottom line: - Longevity is evolving into a measurable, multi-segment market built on aging demographics, clinical validation and AI-enabled discovery, with the biggest growth likely to come from therapies and tools that can prove real-world healthspan gains.